Oncodesign innovate in healthtech since 1995

For more than 25 years, we have been creating new technological pathways to find and select the best drug candidates. From the beginning, we have always tried to establish a continuum between the target and the patients to qualify the potential efficacy of new treatments. We are pioneers in translational medicine, from Artificial Intelligence-powered target identification to new approaches to evaluate the efficacy of treatments, such as pharmaco-imaging.

Working in precision medicine since 1995

VisuelOPM-accord
2022

IPO - OPM

OPM went public on Euronext Growth in Paris.

VisuelOPM-IA
2022

STarT project with Servier

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment

Cancer-visuel-accord-SEngine
2022

Partnership with SEngine

Oncodesign signed a research collaboration agreement with SEngine Precision Medicine, a precision oncology company for the discovery of a new personalized cancer treatment for aggressive and untreatable tumors.

Partenariat-avec-Servier
2019

Partnership with Servier

Oncodesign signed a strategic R&D collaboration with the pharmaceutical company Servier to identify a new drug candidate in order to better combat Parkinson’s disease.

Florepizol-entre-en-phase-clinique
2016

Florepizol entered clinical testing

Oncodesign launched its first clinical study with its PET (positron emission tomography) radiotracer in patients with non-small cell lung cancer. Florepizol is used to identify mutated forms of EGFR in patients with non-small cell lung cancer. Tumors with an EGFR-activating mutation may be treated with tyrosine kinase inhibitors. Relevant clinical data collected in this way are an innovative method of precision medicine for the good of the patient.

Acquisition-du-site-de-GSK
2016

Acquisition of the GSK site

Oncodesign acquired the Ulis Research Center, with more than 50 highly qualified employees working in drug discovery, specifically in medicinal chemistry, biology, in vivo pharmacology and drug metabolism/pharmacokinetics. This acquisition strengthened Oncodesign’s pharmacological platform and medicinal chemistry capabilities, enabling it to leverage a performing Drug Discovery platform for its own programs and to offer integrated drug discovery services from start to finish.

Nanocyclix
2010

Nanocyclix®

Oncodesign targets kinases, a family of enzymes that play a key role in maintaining cellular homeostasis which, if disrupted, is involved in more than 400 diseases. Nanocyclix® is a proprietary medicinal chemistry technology based on the macrocyclization of small molecules to discover effective treatments for patients with unmet medical needs.

pharminage-oncodesign-pm
2008

Pharmimage

Created by Oncodesign, Pharmimage is a regional center of excellence for pharmaco-imaging aimed at assessing the effects of treatments and identifying biomarkers based on their translational efficacy for precision medicine. This complex located in Dijon, France, brings together hospitals, as well as biotechnology and pharmaceutical companies.

philippe-genne-photo-carre
1995

Creation

Creation by its CEO and founder Philippe Genne, in Dijon, as a pharmacology services company to select the best oncology drug candidates.

visuel-neurone
2022

LRRK2 enters clinical phase

Servier and OPM announce that Servier has exercised its exclusive license option for their drug candidate, an inhibitor of the LRRK2 (Leucine-Rich-Repeat Kinase 2) kinase target. A Phase 1 study in healthy volunteers, sponsored by Servier, is planned before the end of 2022.

VisuelOPM-batiment
2022

Restructuration of Oncodesign

Oncodesign separates its business lines service and biotech including AI in 2 companies : Oncodesign Services & Oncodesign Precision Medicine

tiumbio-oncodesign-pm
2021

Partnership with TiumBio

Oncodesign signed a strategic R&D collaboration with TiumBio, specialized in rare diseases, to identify new drug candidates to treat fibrosis.

fond-laboratoire
2017

Acquisition of the pharmaceutical and biotech services activities of Bertin Pharma

Oncodesign acquired activities in metabolism, pharmacokinetics, bioanalysis and translational medicine, with more than 45 qualified employees in immunology and infectious diseases. This acquisition strengthened Oncodesign’s offering in the field of immunology and infectious diseases, as well as its capabilities in ADME, regulatory bioanalysis and biobank management.

OncoSNIPE
2016

OncoSNIPE®

A Structuring Project for Competitiveness (PSPC) as part of the Investments for the Future Program (PIA) coordinated by Oncodesign was launched to develop and apply artificial intelligence techniques to cancer research. A missing link between target identification and patients, the OncoSNIPE® program is used to guide new drug discovery programs in precision medicine.

imodi-oncodesign-pm
2013

IMODI®

In collaboration with 21 partners, Oncodesign launched a French consortium to develop new experimental models for eight oncology indications in order to improve the selection of effective diagnostic and therapeutic compounds.

imakinib-oncodesign-pm
2009

IMAkinib®

Oncodesign receives a €10 million grant for the IMAkinib® biomarker program in oncology. The French Innovation Agency OSEO is funding the 8-year collaborative project with the goal of improving cancer treatment through new specific radiotracers.

Concept-Medicine-Precision-AdobeStock_208130179
2005

C.Re.M.E.C (Experimental Cancer Models Resource Center)

Oncodesign launched the C.Re.M.E.C (Experimental Cancer Models Resource Center) project, the first project approved by the Medicen competitiveness complex.

VisuelOPM-accord
2022

IPO - OPM

OPM went public on Euronext Growth in Paris.

visuel-neurone
2022

LRRK2 enters clinical phase

Servier and OPM announce that Servier has exercised its exclusive license option for their drug candidate, an inhibitor of the LRRK2 (Leucine-Rich-Repeat Kinase 2) kinase target. A Phase 1 study in healthy volunteers, sponsored by Servier, is planned before the end of 2022.

VisuelOPM-IA
2022

STarT project with Servier

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment

VisuelOPM-batiment
2022

Restructuration of Oncodesign

Oncodesign separates its business lines service and biotech including AI in 2 companies : Oncodesign Services & Oncodesign Precision Medicine

Cancer-visuel-accord-SEngine
2022

Partnership with SEngine

Oncodesign signed a research collaboration agreement with SEngine Precision Medicine, a precision oncology company for the discovery of a new personalized cancer treatment for aggressive and untreatable tumors.

tiumbio-oncodesign-pm
2021

Partnership with TiumBio

Oncodesign signed a strategic R&D collaboration with TiumBio, specialized in rare diseases, to identify new drug candidates to treat fibrosis.

Partenariat-avec-Servier
2019

Partnership with Servier

Oncodesign signed a strategic R&D collaboration with the pharmaceutical company Servier to identify a new drug candidate in order to better combat Parkinson’s disease.

fond-laboratoire
2017

Acquisition of the pharmaceutical and biotech services activities of Bertin Pharma

Oncodesign acquired activities in metabolism, pharmacokinetics, bioanalysis and translational medicine, with more than 45 qualified employees in immunology and infectious diseases. This acquisition strengthened Oncodesign’s offering in the field of immunology and infectious diseases, as well as its capabilities in ADME, regulatory bioanalysis and biobank management.

Florepizol-entre-en-phase-clinique
2016

Florepizol entered clinical testing

Oncodesign launched its first clinical study with its PET (positron emission tomography) radiotracer in patients with non-small cell lung cancer. Florepizol is used to identify mutated forms of EGFR in patients with non-small cell lung cancer. Tumors with an EGFR-activating mutation may be treated with tyrosine kinase inhibitors. Relevant clinical data collected in this way are an innovative method of precision medicine for the good of the patient.

OncoSNIPE
2016

OncoSNIPE®

A Structuring Project for Competitiveness (PSPC) as part of the Investments for the Future Program (PIA) coordinated by Oncodesign was launched to develop and apply artificial intelligence techniques to cancer research. A missing link between target identification and patients, the OncoSNIPE® program is used to guide new drug discovery programs in precision medicine.

Acquisition-du-site-de-GSK
2016

Acquisition of the GSK site

Oncodesign acquired the Ulis Research Center, with more than 50 highly qualified employees working in drug discovery, specifically in medicinal chemistry, biology, in vivo pharmacology and drug metabolism/pharmacokinetics. This acquisition strengthened Oncodesign’s pharmacological platform and medicinal chemistry capabilities, enabling it to leverage a performing Drug Discovery platform for its own programs and to offer integrated drug discovery services from start to finish.

imodi-oncodesign-pm
2013

IMODI®

In collaboration with 21 partners, Oncodesign launched a French consortium to develop new experimental models for eight oncology indications in order to improve the selection of effective diagnostic and therapeutic compounds.

Nanocyclix
2010

Nanocyclix®

Oncodesign targets kinases, a family of enzymes that play a key role in maintaining cellular homeostasis which, if disrupted, is involved in more than 400 diseases. Nanocyclix® is a proprietary medicinal chemistry technology based on the macrocyclization of small molecules to discover effective treatments for patients with unmet medical needs.

imakinib-oncodesign-pm
2009

IMAkinib®

Oncodesign receives a €10 million grant for the IMAkinib® biomarker program in oncology. The French Innovation Agency OSEO is funding the 8-year collaborative project with the goal of improving cancer treatment through new specific radiotracers.

pharminage-oncodesign-pm
2008

Pharmimage

Created by Oncodesign, Pharmimage is a regional center of excellence for pharmaco-imaging aimed at assessing the effects of treatments and identifying biomarkers based on their translational efficacy for precision medicine. This complex located in Dijon, France, brings together hospitals, as well as biotechnology and pharmaceutical companies.

Concept-Medicine-Precision-AdobeStock_208130179
2005

C.Re.M.E.C (Experimental Cancer Models Resource Center)

Oncodesign launched the C.Re.M.E.C (Experimental Cancer Models Resource Center) project, the first project approved by the Medicen competitiveness complex.

philippe-genne-photo-carre
1995

Creation

Creation by its CEO and founder Philippe Genne, in Dijon, as a pharmacology services company to select the best oncology drug candidates.

Read the last news

Financial
Press Release
Wed. 28 September 2022
Oncodesign and OPM announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access+ market...